title: Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors.
abstract: Primitive malignant progenitors defined as nonobese diabetic/severe combined immunodeficient (NOD/SCID) leukemia-initiating cells or NOD/SL-IC from patients with acute myeloid leukemia (AML) can be detected and quantitated in sublethally irradiated NOD/SCID mice. However, there is variability in the levels of bone marrow (BM) engraftment obtained after intravenous injection of cells from different AML samples. In the current study, AML cell engraftment in standard NOD/SCID mice was compared to that obtained with NOD/SCID mice transgenic for the human growth factor genes Steel factor (SF), interleukin-3 (IL-3) and granulocyte macrophage-colony-stimulating factor (GM-CSF) (N/S-S/GM/3) as well as beta 2 microglobulin-null NOD/SCID (N/S-beta 2m(-/-)) mice. Three of the eight AML samples that failed to engraft in standard NOD/SCID animals showed easily detectable and up to 70-fold increased in the number of leukemic cells in BM 8-12 weeks post-transplantation in each of the N/S-beta 2m(-/-) and N/S-S/GM/3 mouse strains. In two of the four AML samples studied at limiting dilution, the frequency of NOD/SL-IC detected was increased six- and seven-fold. Thus, in these novel mouse strains a broader spectrum of AML patient samples can be evaluated for their progenitor content and potentially studied for their response to innovative therapeutics in vivo.
authors.affiliation: The Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Feuring-Buske
authors.forename: B
authors.initials: B
authors.lastname: Gerhard
authors.forename: J
authors.initials: J
authors.lastname: Cashman
authors.forename: R K
authors.initials: RK
authors.lastname: Humphries
authors.forename: C J
authors.initials: CJ
authors.lastname: Eaves
authors.forename: D E
authors.initials: DE
authors.lastname: Hogge
mesh_terms: D000208:Acute Disease; D000818:Animals; D001853:Bone Marrow / Q000473:pathology; D005434:Flow Cytometry; D006085:Graft Survival; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000235:genetics / Q000502:physiology*; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007377:Interleukin-3 / Q000235:genetics / Q000502:physiology*; D007951:Leukemia, Myeloid / Q000473:pathology*; D051379:Mice; D016688:Mice, Inbred NOD; D018345:Mice, Knockout; D016513:Mice, SCID; D008822:Mice, Transgenic; D009368:Neoplasm Transplantation; D011828:Radiation Chimera; D011993:Recombinant Fusion Proteins / Q000502:physiology; D019089:Stem Cell Factor / Q000235:genetics / Q000502:physiology*; D014183:Transplantation, Heterologous; D001613:beta 2-Microglobulin / Q000172:deficiency* / Q000235:genetics
chemical_list: D007377:Interleukin-3; D011993:Recombinant Fusion Proteins; D019089:Stem Cell Factor; D001613:beta 2-Microglobulin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor